CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 1,019,491	$ 812,733
Marketable securities	605,461	596,847
Accounts receivable - trade, net	1,531,936	1,538,642
Accounts Receivable from Sanofi	168,855	193,684
Accounts receivable from Bayer	243,141	242,014
Inventories	820,397	726,138
Prepaid expenses and other current assets	155,451	224,972
Total current assets	4,544,732	4,335,030
Marketable securities	1,821,985	1,486,494
Property, Plant, and Equipment, Net	2,394,727	2,358,605
Deferred tax assets	532,268	506,291
Other assets	78,984	77,866
Total assets	9,372,696	8,764,286
Current liabilities:
Accounts Payable	207,611	178,183
Accrued Liabilities and Other Liabilities	666,216	637,162
Deferred revenue from Sanofi, current portion	231,447	177,746
Deferred Revenue, Current	160,466	142,392
Total current liabilities	1,265,740	1,135,483
Capital and facility lease obligations	704,645	703,453
Deferred revenue from Sanofi	406,778	379,936
Deferred Revenue, Noncurrent	257,967	249,263
Other long-term liabilities	169,922	152,073
Total liabilities	2,805,052	2,620,208
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	3,611,599	3,512,833
Retained earnings	3,287,767	2,946,733
Accumulated other comprehensive income (loss)	(15,594)	640
Treasury stock	(316,240)	(316,240)
Total stockholders' equity	6,567,644	6,144,078
Total liabilities and stockholders' equity	9,372,696	8,764,286
Class A Stock
Stockholders' equity:
Common stock	2	2
Common Stock
Stockholders' equity:
Common stock	$ 110	$ 110